跳至主要内容

Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration

 On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug.  The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.

AnDiCon Bio and Medicilon-1.jpg

It is worth mentioning that ADC189 will also add new research on pediatric indications while starting the clinical phase II/III trial.  Shanghai Medicilon Inc (Medicilon) is fortunate to undertake the formulation R&D of ADC189, helping the class 1 anti-influenza new drug ADC189 to benefit more patients.

ADC189 has launched clinical phase II/III, which is an important breakthrough in the field of anti-infection of the respiratory tract in China, and is also a testimony to the independent R&D strength of AnDiCon.  Medicilon, which also focuses on innovation, has vigorously entered the CDMO field in recent years.  Currently, Medicilon preparation CDMO can undertake the whole process of preparation R&D from project evaluation, pre-prescription research, preparation process research, quality research, clinical sample production, stability research and registration, which assist the R&D of innovative drugs.  A number of innovative drugs have completed formulation development, which were successfully approved for clinical use, through Medicilon's high-end formulation technology platforms, such as inhalation drug research and development platform, ophthalmic drug research and development platform, and topical skin preparation research and development platform.

Up to now, Medicilon has undertaken more than 100 IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of May 2022, Medicilon has successfully helped 10 ADC drugs to be approved for clinical trails, and has multiple ADC projects under development. Medicilon has in-depth exchanges with customers in the formulation of the preclinical integrated research plan of ADC. The backbone of scientific research combines the characteristics of each case with years of practical experience and technical accumulation, and carefully submits high-quality experimental plans and results to customers.

About AnDiCon

Led by a number of top domestic scientists and academicians, AnDiCon has an efficient and pragmatic project team with an international perspective.  Relying on the platform advantages of the company's DMPK new drug discovery platform, AnDiCon is committed to solving the accessibility of innovative drugs in the field of respiratory anti-infection and gynecology in China.  AnDiCon's product pipeline also includes urgently needed oral new drugs for endometriosis and uterine fibroids, 3CL protease inhibitory anti-COVID-19 drugs, and anti-RSV drugs.  As a leading Biotech company in the field of respiratory anti-infection and gynecology, AnDiCon has been recognized by many well-known investment institutions.

Medicilon's preparation laboratory and workshop area is about 4,000 square meters, with 100 professional R&D teams, of which more than 40% are masters/doctors, and more than 95% are undergraduates. The team has rich experience in successful research and development of innovative drugs, consistency evaluation, and improved new drugs, and experience in China-US dual filing and project management. The Medicilon pharmaceutical preparation R&D team has successfully cooperated with well-known large and medium-sized pharmaceutical companies worldwide, and has accumulated 18 years of experience in the research and application of innovative drugs and generic drugs. We provide one-stop and systematic preparation R&D services covering innovative drugs and generic drugs to meet the needs of customers at different stages of R&D.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Enzyme Activity Assay Service

  Enzymatic assay Lance Assay Alphascreen Assay Z’-LYTE Assay Adapta Assay Kinase-Glo Assay ADP-Glo Assay Ligand Binding Assay ELISA Assay HTRF Assay Enzyme activity assays  are laboratory methods for measuring enzymatic activity. They are vital for the study of enzyme kinetics and enzyme inhibition. Enzyme units : Amounts of enzymes can either be expressed as molar amounts, as with any other chemical, or measured in terms of activity, in enzyme units. Medicilon provides various  enzyme activity assays  for  kinases , phosphatases, proteinases, deacetylase, peptidase, esterase, and other enzymes. Our line of well-characterized immunoassays and biochemical kits ensures accurate and reproducible results. Enzyme is a  large category of bio-molecules  that catalyze various biological processes including metabolic processes, cellular signaling and regulation, cell division and apoptosis. Enzymatic reactions convert substrate molecules into chemically modified molecules products with high sp